Bringing the very best science and medicine to our best equine friends
Community

KindredBio supports New Horizon Ranch – both working to strengthen the bond between horses and humans

KindredBio is a veterinary biopharmaceutical company based in Burlingame, CA that is focused on a strong development pipeline serving the horse with the motto “best medicines for our best friends.” KindredBio’s co-founder and many employees are horse people and advocates for the bond between horses and people with an understanding of how these animals change people’s lives. The value of the horse goes way beyond high end athletes such as our Olympic horses or Kentucky Derby winners.  Even retired or back yard horses touch human lives in unimaginable ways.  New Horizon ranch is a therapeutic riding center located in Rantoul, ...
Continue Reading

World’s Top Show Jumper, McLain Ward, wins the $15,000 KindredBio Jumper Prix

Saugerties, NY (June 12, 2016) The HITS-on-the-Hudson III at the Grand Prix Stadium saw some excellent competition on Saturday and we were excited to see the action around the $15,000 KindredBio 1.40M Jumper Prix. McLain Ward, a two-time Olympic gold medalist and currently ranked the #1 show jumper in the world, aboard Best Buy, a nine-year-old Holsteiner mare owned by Double H Farm, topped the competition. The team was clean in the first round along with 8 other horse and rider combinations.  Ward and Best Buy had a fast and clean jump-off round, navigating the tough track in a fast …

Continue Reading

Kindred Biosciences Announces HITS Sponsorship

San Francisco, CA (May 25, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, is pleased to announce their Platinum Sponsorship of the HITS Horse Show series.  The sponsorship will start this week at the Saugerties, New York facility for the HITS-on-the-Hudson series and will extend through both the HITS Ocala Winter Circuit in Ocala, Florida, and the HITS Desert Circuit in Thermal, California. Denise Bevers, Co-Founder and Chief Operating Officer, said, “As a company dedicated to developing innovative medications for our horse companions, we are very pleased to be partnering …

Continue Reading

Kindred Biosciences to Announce First Quarter 2016 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Thursday, May 5, 2016 San Francisco, CA (April 25, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its first quarter 2016 financial results on May 5, 2016 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day. Interested parties may access the call by dialing toll-free (855) 433-0927 from the US, or (484) …

Continue Reading

PRESS RELEASE – Kindred Biosciences Submits Final Major New Animal Drug Application Technical Section for Safety for Zimeta to FDA

San Francisco, CA (March 15, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission to FDA of the Safety technical section of the New Animal Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  This is the final major technical section to be submitted for Zimeta. The Chemistry, Manufacturing, and Controls technical section was submitted in December 2015 and the Effectiveness technical section was submitted in February 2016. In the target animal safety study, Zimeta, was well tolerated with no clinically-significant changes when compared to control horses (placebo ...
Continue Reading

Kindred Biosciences Announces Fourth Quarter and Year-End 2015 Financial Results

San Francisco, CA (March 2, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the fourth quarter and full year ended December 31, 2015. “We are very pleased with the progress on Zimeta™, our lead product candidate, and look forward to our first product approval and launch,” stated Richard Chin, M.D., President and CEO of KindredBio. “We are also pleased to report that the strong pipeline of additional products, including KIND-010 for management of weight in cats and feline epo for anemia in cats, are also …

Continue Reading

Kindred Biosciences to Provide Corporate Update via Webcast in Advance of One-on-One Investor Meetings in San Francisco January 12-14, 2016.

San Francisco, CA (January 7, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will provide a corporate update via webcast on Monday, January 11, 2016 in advance of one-on-one investor meetings in San Francisco January 12-14, 2016.

Continue Reading